

Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain

HealthTech guidance

Published: 22 September 2022

www.nice.org.uk/guidance/htg641

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations](#) wherever possible.

Contents

1 Recommendations	4
2 The condition, current treatments and procedure.....	6
The condition.....	6
Current treatments.....	6
The procedure	6
3 Committee considerations	8
The evidence	8
Committee comments.....	8
Update information	10

This guidance replaces IPG739.

1 Recommendations

- 1.1 Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what [special arrangements](#) mean on the [NICE guidance page](#).
- 1.2 Clinicians wanting to do neurostimulation of lumbar muscles for refractory non-specific chronic low back pain should:
 - Inform the clinical governance leads in their healthcare organisation.
 - Give people (and their families and carers as appropriate) clear written information to support [shared decision making](#), including [NICE's information for the public](#).
 - Ensure that people (and their families and carers as appropriate) understand the procedure's safety and efficacy, and any uncertainties about these.
 - Audit and review clinical outcomes of everyone having the procedure. The main efficacy and safety outcomes identified in this guidance can be entered into [NICE's audit tool](#) (for use at local discretion).
 - Enter details about everyone having neurostimulation of lumbar muscles for refractory non-specific chronic low back pain onto the [National Neuromodulation Registry](#) and review local clinical outcomes.
- 1.3 Healthcare organisations should:
 - Ensure systems are in place that support clinicians to collect and report data on outcomes and safety for everyone having this procedure.
 - Regularly review data on outcomes and safety for this procedure.

- 1.4 Patient selection should be done by a multidisciplinary team with experience in pain management and neuromodulation stimulation procedures.
- 1.5 Further research should include suitably powered randomised controlled trials comparing the procedure with current best practice with appropriate duration. It should report details of patient selection and long-term outcomes.

2 The condition, current treatments and procedure

The condition

- 2.1 Non-specific severe long-term chronic refractory low back pain can present in various ways, including as neuropathic pain (associated with damage to the nervous system) or nociceptive pain (associated with physical damage to joints, muscles and ligaments). In some people, it is associated with dysfunction of the lumbar multifidus (large muscles that support the lower back) and arthrogenic muscle inhibition. This treatment is not intended for neuropathic pain.

Current treatments

- 2.2 Treatments for low back pain are described in [NICE's guideline on low back pain and sciatica in over 16s: assessment and management](#). Conservative pain management includes pharmacological treatments (such as oral non-steroidal anti-inflammatory drugs, and weak opioids with or without paracetamol) and non-interventional treatments (such as self-management advice and education, exercise, manual therapies, and combined physical and psychological therapy). People with severe chronic low back pain that is refractory to conservative treatments may be offered interventional procedures (such as radiofrequency denervation and epidural injections) or surgery (such as spinal fusion procedures).

The procedure

- 2.3 The procedure is done under general anaesthesia, or local anaesthesia with sedation. A pulse generator (neurostimulator) is implanted in a pocket created under the skin of the upper buttock or lower back. Under fluoroscopic guidance through a midline approach, 2 stimulating leads are inserted. The distal end of

each lead has stimulation electrodes. They are positioned next to the spinal column, near the medial branch of the L2 motor nerve supply (dorsal ramus nerve) to the multifidus muscles, and fixed using flexible tines. The leads are tunnelled internally, then the proximal ends are connected to the pulse generator and the position is checked radiographically.

- 2.4 Approximately 14 days after the implantation procedure, the patient can start to use the device to manage their pain. While lying prone, they use a handheld wireless remote control to deliver stimulation to the nerve supply of the lumbar multifidus muscles, which causes them to contract. This is usually done twice a day for about 30 minutes each time. The pulse generator can be programmed to deliver stimulation between any pair of electrodes on each lead if needed.
- 2.5 The aim of neurostimulation is to help the body regain multifidus neuromuscular control by 'activating' the lumbar muscles and stabilising the spinal column, reducing chronic pain. The procedure is reversible.

3 Committee considerations

The evidence

- 3.1 NICE did a rapid review of the published literature on the efficacy and safety of this procedure. This comprised a comprehensive literature search and detailed review of the evidence from 6 sources, which was discussed by the committee. The evidence included 1 randomised controlled trial (described in 2 publications), 1 case series (described in 2 publications) and another 2 case series. It is presented in the [summary of key evidence section in the overview](#). Other relevant literature is in the appendix of the overview.
- 3.2 The professional experts and the committee considered the key efficacy outcomes to be: patient-reported outcome measures including reduction in back pain, improved quality of life and improved activities of daily living.
- 3.3 The professional experts and the committee considered the key safety outcomes to be: lead fracture, lead migration, infection, pain, pulse generator failure and need for early removal.
- 3.4 Twenty-two commentaries from patients who have had this procedure were discussed by the committee.

Committee comments

- 3.5 The committee was informed that there have been changes in the leads used in the device and in the surgical technique used to implant them, which have reduced the risk of lead fractures and migration. The majority of the adverse events came from earlier devices.
- 3.6 The devices are not MRI compatible, but research is ongoing to make them safe in some scanners (MRI conditional).

- 3.7 The committee noted that the majority of the research is in younger patients with a body mass index below 35.

Update information

Minor changes since publication

January 2026: Interventional procedures guidance 739 has been migrated to HealthTech guidance 641. The recommendations and accompanying content remain unchanged.

ISBN: 978-1-4731-8546-3

Endorsing organisation

This guidance has been endorsed by [Healthcare Improvement Scotland](#).